Jump to main content
Takeda, in alignment with the U.S. Food and Drug Administration (FDA), will close the U.S. Special Use Program (SUP) for NATPARA® (parathyroid hormone) for Injection at the end of 2025. TAKEDA WILL CEASE SHIPMENTS OF NATPARA BY DECEMBER 31, 2025 AND NATPARA WILL NO LONGER BE AVAILABLE TO SUP PATIENTS. Learn How This May Affect You
NATPARA logo.
NATPARA logo.

Contact Us

Takeda

500 Kendall Square

Cambridge, MA 02142

www.Takeda.com

Media requests

NATPARA® and the NATPARA Logo® are registered trademarks of Takeda Pharmaceuticals, U.S.A,. Inc.